Global In Vitro Fertilization Market Set to Reach $1.65 Billion by 2029 Amid Rising Infertility Rates and Technological Advancements

 The global In Vitro Fertilization (IVF) market is poised for robust expansion, projected to grow from USD 949 million in 2024 to USD 1,650 million by 2029, registering a CAGR of 11.7% during the forecast period. This growth trajectory underscores the increasing clinical adoption of assisted reproductive technologies and the evolving dynamics of fertility care worldwide.

The market’s upward momentum is primarily driven by the rising prevalence of infertility, closely linked to delayed parenthood, lifestyle changes, and underlying medical conditions. As fertility challenges become more common across both developed and emerging economies, demand for IVF solutions continues to accelerate among individuals and couples seeking effective reproductive outcomes.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89198891

Advanced IVF Equipment Driving Market Expansion

The IVF equipment segment is expected to witness significant growth through 2029, reflecting the critical role of precision technologies in improving clinical success rates.

Key equipment such as micromanipulators, imaging systems, incubators, and microscopes are central to optimizing every stage of the IVF process—from gamete evaluation to embryo development. High-performance incubators ensure controlled environments for embryo viability, while advanced imaging and microscopy solutions enable clinicians to make data-driven decisions. Additionally, innovations in sperm preparation and embryo transfer technologies are enhancing procedural efficiency and treatment outcomes, reinforcing the strategic importance of equipment investments for fertility clinics.

Fresh Non-Donor IVF Cycles Maintain Market Leadership

By cycle type, fresh non-donor IVF accounted for the largest market share in 2023 and is expected to maintain its dominance. This preference is largely attributed to its use of patients’ own genetic material, aligning with cultural and personal considerations while offering improved success rates.

Fresh cycles are often perceived as more cost-effective and time-efficient compared to donor or frozen embryo alternatives. Continuous technological advancements have further enhanced success rates, making fresh IVF a preferred option for both patients and clinicians. The ability to personalize treatment protocols based on individual fertility profiles also contributes to its widespread adoption.

Asia Pacific Emerges as a High-Growth Regional Hub

While North America held the largest market share in 2023, the Asia Pacific region is rapidly establishing itself as a key growth engine in the global IVF landscape.

Factors such as increasing infertility rates, rising disposable incomes, and expanding healthcare infrastructure are fueling market growth across countries like China, India, and Southeast Asia. Growing awareness and social acceptance of assisted reproductive technologies, coupled with supportive government initiatives, are further accelerating adoption.

The region’s combination of advanced medical capabilities, cost-effective treatment options, and skilled fertility specialists is positioning Asia Pacific as a preferred destination for both domestic and international patients seeking IVF treatments.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=89198891

Competitive Landscape

The IVF market is characterized by the presence of several established players focusing on innovation, strategic collaborations, and global expansion. Key companies operating in this space include: CooperSurgical inc. (US) Cook group (US) , Vitrolife(Sweden), Hamilton thorne ltd. (US), Fujifilm Irvine scientific (Japan), among others.

These organizations are actively investing in advanced reproductive technologies and expanding their global footprint to capitalize on the growing demand for fertility treatments.

Strategic Outlook

As infertility rates continue to rise and patient awareness increases, the IVF market is transitioning into a high-growth, innovation-driven segment within the broader healthcare ecosystem. Stakeholders across the value chain—from equipment manufacturers to fertility clinics—are expected to benefit from sustained demand, technological advancements, and expanding access to reproductive healthcare services.

Patient Registry Software Market to Reach $3.61 Billion by 2030, Fueled by Real-World Evidence Demand and Digital Health Expansion

 The global Patient registry software market is projected to grow from USD 2.25 billion in 2025 to USD 3.61 billion by 2030, at a CAGR of 9.8%. This growth highlights the growing importance of structured, real-world data in shaping modern healthcare delivery and policy. As healthcare systems increasingly rely on data-driven decision-making, patient registry software is emerging as a critical tool for improving clinical outcomes and advancing research. 

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144694594

What is driving the rapid adoption of patient registry software?

A key factor is the rising demand for real-world evidence (RWE) across healthcare research, regulatory decision-making, and policy development. At the same time, increasing adoption of electronic health records (EHRs) is enabling seamless data capture and integration, making registries more efficient and scalable. Why does this matter now? As healthcare systems shift toward value-based care, the need for accurate, longitudinal patient data is becoming essential.

How are use cases evolving across the healthcare ecosystem?

Patient registry software is playing a pivotal role in chronic disease management, clinical research, and population health initiatives. Government-led programs promoting patient-centered care and disease-specific registries—covering conditions such as cancer, diabetes, cardiovascular diseases, and rare disorders—are accelerating adoption. Additionally, the transition to cloud-based platforms and subscription-based pricing models is lowering entry barriers for hospitals, pharmaceutical companies, and research organizations.

Which segment leads the market today?

The disease registries segment accounted for the largest share in 2025. This dominance is driven by the increasing prevalence of chronic and rare diseases worldwide. Disease registries enable early diagnosis, support targeted therapy development, and provide structured datasets for clinical and epidemiological research. With millions of patients affected globally, the need for comprehensive disease tracking and outcome monitoring continues to rise.

Which segment is expected to grow the fastest?

Site-based or clinical data (provider-recorded) registries are projected to register the highest CAGR during the forecast period. These registries offer high-quality, reliable data captured directly at the point of care by healthcare professionals. Their integration with EHR systems enhances data accuracy, reduces administrative burden, and supports evidence-based medicine, regulatory compliance, and quality reporting initiatives.

Where are the strongest growth opportunities emerging?

The Asia Pacific region is expected to witness significant growth, driven by rapid advancements in digital health infrastructure and increasing government investments in healthcare IT. Countries such as India, China, Japan, and South Korea are actively promoting patient registry initiatives to improve disease management and clinical research. Expanding pharmaceutical R&D activities and regulatory reforms are further accelerating adoption across the region.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=144694594

Market Insights:

Who are the key players shaping this dynamic market? Leading companies include IBM, IQVIA Holdings Inc., Health Catalyst Inc., Oracle, UnitedHealth Group, Conduent Inc., and Elekta. These organizations are focusing on advanced analytics, interoperability, and scalable cloud-based solutions to strengthen their competitive positioning.